TRAIL-R2 Antibody [HS201] (biotin)

ProSci
Product Code: PSI-36-130
Product Group: Primary Antibodies
Supplier: ProSci
CodeSizePrice
PSI-36-130-100ug100ug£729.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: HS201
Regulatory Status: RUO
Target Species: Human
Applications:
  • Flow Cytometry
  • Functional Study
  • Immunocytochemistry (ICC)
  • Immunohistochemistry (IHC)
  • Immunoprecipitation (IP)
Storage:
Stable for at least 1 year after receipt when stored at -20˚C.

Further Information

Additional Names:
TRAIL Receptor 2; DR5; KILLER; TNFRSF10B; CD262
Application Note:
Functional Application: Inhibition (blocks TRAIL-R2 mediated killing if applied in solution). Immunohistochemistry: (paraffin sections, 15ug/ml).
Background:
TRAIL-R2 is a receptor for the cytotoxic ligand TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappaB.
Buffer:
Liquid. In PBS containing 0.02% sodium azide.
Concentration:
0.5 mg/ml
Conjugate:
Biotin
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Recombinant human TRAIL-R2 (DR5).
NCBI Gene ID #:
8795
NCBI Official Name:
tumor necrosis factor receptor superfamily, member 10b
NCBI Official Symbol:
TNFRSF10B
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
2338419
Protein GI Number:
AF012535
Purification:
>95% (SDS-PAGE)
Research Area:
Apoptosis,Cancer,Immunology,Functional Assays
SPECIFICITY:
Recognizes human TRAIL-R2. Does not cross-react with human TRAIL-R1, -R3 or -R4.
Swissprot #:
O14763
User NOte:
Optimal dilutions for each application to be determined by the researcher.